Tag: paclitaxel-coated device

Nationwide study identifies sex disparities in long-term mortality after paclitaxel exposure

A German claims-based cohort study has revealed that—in 13,204 patients treated with a paclitaxel-coated device for peripheral arterial disease (PAD)—mortality differences were mostly attributable...

ACC.21: SAFE-PAD finds no increased risk of death with drug-coated devices...

Researchers have found no statistically significant difference in mortality between patients treated with drug-coated devices and non-drug-coated devices in the SAFE-PAD study. Eric Secemsky...

CX 2020 encourages vascular community to strive for consensus

The Charing Cross Symposium (CX; 21–24 April, London, UK) is the longest-running vascular and endovascular global symposium, and an important source of Education, Innovation,...

No evidence of increased mortality with paclitaxel-based devices in German claim...

A real-world safety analysis of paclitaxel-based devices in peripheral arteries, recently published in the European Heart Journal, showed no evidence for increased mortality over...

CIRSE 2019: New Cook Medical paclitaxel data confirm safety of Zilver...

New data on the use of Zilver PTX, Cook Medical’s paclitaxel-coated stent for peripheral arterial disease (PAD), confirm the safety of the device. These...

UK MHRA forms Expert Advisory Group to review paclitaxel devices while...

The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK and the Food and Drug Administration (FDA) in the USA have both recently...
paclitaxel

Without additional long-term and patient-level data, Katsanos et al’s conclusion is...

By Thomas Zeller The Katsanos et al meta-analysis reports an increased risk of mortality beyond one year across randomised studies of paclitaxel-coated balloons (DCB) and...